Phase 2 Study clinical trials

Olverembatinib for newly diagnosed chronic phase CML

This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.

New drug plus standard chemo for spread colorectal cancer

This trial tests a new drug called SAR445877 combined with two standard chemotherapies (FOLFOX and bevacizumab) as an initial treatment for people whose colorectal cancer has spread and is microsatellite stable (MSS). It aims to see if adding this drug works better than standard therapy alone.

Studying elecoglipron for type 2 diabetes

This trial tests a new medicine called elecoglipron, taken alone or with another diabetes drug (dapagliflozin), to see if it helps control blood sugar better than a placebo. It may be an option if your current treatment isn't working well enough.

CM326 for moderate to severe COPD

This trial tests a new medicine called CM326 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve lung function.

Study of Flonoltinib for Polycythemia Vera

This study tests a new oral drug called Flonoltinib for people with polycythemia vera (PV) that is not well-managed with standard treatments. It aims to see if it can reduce the need for phlebotomies (blood draws) and control your blood counts.

Radotinib for CML patients after prior TKI failure

This trial tests radotinib (a targeted pill) in people with chronic-phase Philadelphia chromosome–positive CML whose previous TKIs stopped working or could not be tolerated. It aims to improve control of the leukemia while checking safety.

Study of APX-343A alone or with pembrolizumab for advanced solid tumors

This trial tests a new drug called APX-343A, either by itself or in combination with the immunotherapy pembrolizumab, for people with advanced solid tumors that have not responded to prior treatments.

HLX43 for advanced nasopharyngeal cancer after prior treatments

This trial tests an investigational drug called HLX43 for people with nasopharyngeal cancer that has come back or spread, and who have already tried two or more prior treatments without success. The goal is to see if HLX43 can shrink tumors or slow the cancer's growth.

Study of dostarlimab and bevacizumab for recurrent clear cell cancer

This trial tests a drug called dostarlimab alone or with bevacizumab compared to standard chemotherapy for women whose clear cell cancer of the ovary, uterus, cervix, vagina, or vulva has come back within a year of platinum chemotherapy. The goal is to see if these newer treatments can help control the cancer better.

Study of TLC-2716 for high triglycerides and fatty liver disease

This trial tests an investigational drug called TLC-2716 for people with very high triglycerides and a type of fatty liver disease (NAFLD or NASH). The goal is to see if it is safe and can help lower fat levels in the blood and liver.

Pre-surgery treatment for stage II-III lung cancer

This study tests two investigational drugs (HLX43 and serplulimab) given before surgery to people with stage II to III non-small cell lung cancer (NSCLC). The goal is to see if these drugs can shrink the tumor and make it easier to remove completely during surgery.

Artesunate ointment for high-grade vulvar lesions

This trial tests an artesunate ointment for women with high-grade vulvar lesions caused by HPV. It aims to see if the ointment can help the lesions heal or disappear without needing surgery.

Durvalumab for cancer after stopping immune therapy due to side effects

This Phase 2 trial tests whether durvalumab (an immunotherapy) can still help treat advanced cancer after you had to stop an earlier immune checkpoint medicine because of immune-related side effects. If you’re already on a durvalumab-based study, Substudy B also looks at continuing durvalumab (with or without tremelimumab) when it’s safe for you.

Study of tulmimetostat and luxdegalutamide for advanced prostate cancer

This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.

Phase II Study of QLC2519 in Pediatric Solid Tumor Participants

A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

Testing HRS-5635 to improve hepatitis B treatment

This study tests whether adding a new drug called HRS-5635 to your current hepatitis B medicine works better than your current treatment alone. You may qualify if your hepatitis B is already controlled with antiviral pills and your viral levels are very low.

Safety study of LTZ-301 for non-Hodgkin lymphoma

This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.

Testing a new drug for Parkinson's disease

This study tests an experimental drug, MTX325, in people with Parkinson's disease. The goal is to see if it is safe and how the body processes it, which may lead to new treatment options.

Study of ZL-6201 for sarcoma and some solid tumors

This trial tests a new drug called ZL-6201 for people with sarcoma or certain solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and helps shrink tumors.

Early study drug for advanced solid tumors, alone or with another drug

This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.

Blood Pressure Medication Study for Japanese Adults

This early-stage trial tests a new blood pressure medication called HJB647 in Japanese adults with elevated or high blood pressure. The study aims to see if the drug is safe and how the body handles it.

Drug combination study for advanced HER2-negative breast cancer

This study tests whether combining two new drugs (AK146D1 and AK112) can help people with advanced breast cancer that is HER2-negative (a type that doesn't have too much of a specific growth protein). The goal is to see if this combination can shrink tumors and improve survival.